Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad's Q4 Revenues Increase 10 Percent on Strong Life Science, Dx Sales

By a GenomeWeb staff reporter

NEW YORK (Genomeweb News) – Bio-Rad reported after the close of the market Wednesday that its fourth-quarter revenues increased 10 percent with both its life sciences and clinical diagnostics segments contributing double-digit increases.

The Hercules, Calif.-based firm brought in total revenues of $495.1 million for the three-month period ended Dec. 31, 2009, compared to $448 million for the fourth quarter of 2008. Its life sciences segment had sales of $191 million, up 12 percent year over year, while its clinical diagnostics sales increased 10 percent to $300.5 million.

The Q4 2009 results beat analysts' consensus expectations of $469.9 million.

Bio-Rad posted a fourth-quarter profit of $37.9 million, or $1.35 per share, compared to a net loss of $8.2 million, or $.30 per share, for Q4 2008. It easily beat analysts' expectations of $1.10 per share.

The 2008 results include $28.8 million in charges for impairment losses on goodwill and long-lived assets. The fourth quarter of 2009 had $3.8 million in such charges.

The firm's R&D spending for the quarter rose 8 percent to $44.5 million from $41.1 million, while its SG&A expenses increased 6 percent to $163.9 million from $154.5 million.

For full-year 2009, Bio-Rad's revenues increased 1 percent to $1.78 billion from $1.76 billion. Excluding currency, its revenues were up 5 percent for the year.

The firm's life sciences segment had sales of $631.5 million, down 2 percent year over year. Sales for the clinical diagnostics segment increased 3 percent to $1.14 billion.

Bio-Rad's net income for the year was $144.6 million, or $5.20 per share, compared to $89.5 million, or $3.24 per share, for full-year 2008.

The firm's R&D spending for the year increased to $163.6 million from $159.5 million, while its SG&A spending increased to $601.5 million from $591.3 million.

Bio-Rad finished the year with cash and cash equivalents of $649.9 million and short-term investments of $94.9 million.

Christine Tsingos, Bio-Rad's CFO, said during a conference call that the firm projects organic revenue growth of around 5 percent for full-year 2010, though reported growth may be higher, especially in the first half of year, depending on currency effects.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.